
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 11 923-928, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
LM McShane, JF Dorgan, S Greenhut and JJ Damato
Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
The laboratory reliability and validity of sex hormone measurements were examined at multiple levels, including lower levels characteristic of children and postmenopausal women. Serum was drawn from four adult male and four adult female healthy volunteers. From each individual's serum pool, a medium- and a low-dilution pool were created. Biochemical analyses for total and non-sex hormone-binding globulin (SHBG)-bound estradiol, estrone, estrone sulfate, progesterone, and SHBG were performed on female samples. Male samples were analyzed for total and non-SHBG-bound testosterone, dihydrotestosterone, androstenedione, and dehydroepiandrosterone sulfate. Two aliquots from each pool were assayed twice in each of two labs. All assays except SHBG in one lab used RIA procedures. Reliability was assessed by variance components analyses and estimated coefficients of variation (CVs). Validity was assessed by comparing observed measurements versus expected values based on known dilution ratios. For the testosterone and dihydrotestosterone assays, CVs were usually less than 10%. For estradiol and progesterone, CVs were usually less than 15%. Assays with larger estimated CVs included androstenedione, dehydroepiandrosterone sulfate, estrone, and estrone sulfate. Absolute levels differed markedly between labs for most assays. Observed measurements generally agreed with values expected from the dilution ratios. A notable exception was the estrone assay at the lowest dilution level, where observed measurements were 2-4 times those expected. A similar but less pronounced overestimation bias for the low levels of estradiol was also suggested. This intra- and interlaboratory variability and apparent low dilution overestimation should be accounted for in studies relating hormones to cancer risk, especially those involving children and postmenopausal women.
This article has been cited by other articles:
![]() |
A. W. Hsing, F. Z. Stanczyk, A. Belanger, P. Schroeder, L. Chang, R. T. Falk, and T. R. Fears Reproducibility of Serum Sex Steroid Assays in Men by RIA and Mass Spectrometry Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1004 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Aksglaede, A. Juul, H. Leffers, N. E. Skakkebaek, and A.-M. Andersson The sensitivity of the child to sex steroids: possible impact of exogenous estrogens Hum. Reprod. Update, July 1, 2006; 12(4): 341 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Tworoger, Y. Yasui, L. Chang, F. Z. Stanczyk, and A. McTiernan Specimen Allocation in Longitudinal Biomarker Studies: Controlling Subject-Specific Effects by Design Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1257 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Colburn Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing J. Clin. Pharmacol., April 1, 2003; 43(4): 329 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rinaldi, H. Dechaud, C. Biessy, V. Morin-Raverot, P. Toniolo, A. Zeleniuch-Jacquotte, A. Akhmedkhanov, R. E. Shore, G. Secreto, A. Ciampi, et al. Reliability and Validity of Commercially Available, Direct Radioimmunoassays for Measurement of Blood Androgens and Estrogens in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 757 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Muti Correspondence re: S. A. Khan et al., The Normal Breast Epithelium of Women with Breast Cancer Displays an Aberrant Response to Estradiol. Cancer Epidemiol. Biomark. Prev., 8: 867-872, 1999 Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 535 - 535. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |